The significance of very low-level viraemia detected by sensitive viral load assays in HIV infected patients on HAART

Journal of Infection

Volumn 62, Issue 1, 2011, Pages 87-92

  Widdrington, John ^a   Payne, Brendan ^a,c   Medhi, Manjul ^b   Valappil, Manoj ^b   Schmid, Matthias L ^a  

^a ROYAL VICTORIA INFIRMARY   (United Kingdom)

^b NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

HAART; HIV infection; HIV 1 quantification; Low level viraemia; Suppression

Indexed keywords

ABACAVIR; ABACAVIR PLUS EFAVIRENZ PLUS TENOFOVIR; ABACAVIR PLUS LAMIVUDINE; ABACAVIR PLUS LAMIVUDINE PLUS NEVIRAPINE; ANTIRETROVIRUS AGENT; ATAZANAVIR PLUS RITONAVIR; DIDANOSINE; DIDANOSINE PLUS EFAVIRENZ PLUS LAMIVUDINE; DIDANOSINE PLUS EFAVIRENZ PLUS NEVIRAPINE; DIDANOSINE PLUS EFAVIRENZ PLUS TENOFOVIR; DIDANOSINE PLUS LAMIVUDINE PLUS NEVIRAPINE; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR; EFAVIRENZ PLUS LAMIVUDINE PLUS STAVUDINE; EMTRICITABINE; EMTRICITABINE PLUS NEVIRAPINE PLUS TENOFOVIR; FOSAMPRENAVIR PLUS RITONAVIR; LAMIVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS TENOFOVIR; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; NEVIRAPINE PLUS TENOFOVIR PLUS ZIDOVUDINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS RNA; ZIDOVUDINE;

ADULT; AGED; ARTICLE; ASSAY; CASE CONTROL STUDY; CONTROLLED STUDY; DRUG TREATMENT FAILURE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; MAJOR CLINICAL STUDY; MALE; NONHUMAN; OUTCOME ASSESSMENT; PREDICTION; RETROSPECTIVE STUDY; RNA ANALYSIS; TREATMENT RESPONSE; VERY LOW LEVEL VIREMIA; VIRAL LOAD ASSAY; VIREMIA; VIRUS LOAD;

ADULT; AGED; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VIRAL LOAD; VIREMIA;

EID: 78751616765     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jinf.2010.11.001     Document Type: Article

References (18)

1. Gazzard B.G., Anderson J., Babiker A., Boffito M., Brook G., Bough G., et al. British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med 2008, 9:563-608.
2. Murray J.S., Elashoff M.R., Iacono-Connors L.C., Cvetkovich T.A., Struble K.A. The use of plasma HIV RNA as a study endpoint in efficacy trials of antiretroviral drugs. AIDS 1999, 13(7):797-804.
3. Verhofstede C., Van Wanzeele F., Reynaerts J., Mangelschots M., Plum J., Fransen K. Viral load assay sensitivity and low level viraemia in HAART treated HIV patients. J Clin Virol 2010, 10.1016/j.jcv.2010.01.008.
4. Cohen C. Low-level viraemia in HIV-1 infection: consequences and implications for switching to a new regimen. HIV Clin Trials 2009, 10(2):116-124.
5. Sungkanuparph S., Groger R.K., Overton E.T., Fraser V.J., Powderly W.G. Persistent low-level viraemia and virological failure in HIV-1-infected patients treated with highly active antiretroviral therapy. HIV Med 2006, 7(7):437-441.
6. Havlir D.V., Strain M.C., Clerici M., Ignacio C., Trabattoni D., Ferrante P., et al. Productive infection maintains a dynamic steady state of residual viremia in human immunodeficiency virus type 1-infected persons treated with suppressive antiretroviral therapy for five years. J Virol 2003, 77(20):11212-11219.
7. Pozniak A., Gupta R.K., Pillay D., Arribas J., Hill A. Causes and consequences of incomplete HIV RNA suppression in clinical trials. HIV Clin Trials 2009, 10(5):289-298.
8. Palmisano L., Giuliano M., Nicastri E., Pirillo M.F., Andreotti M., Galluzzo C.M., et al. Residual viraemia in subjects with chronic HIV infection and viral load <50copies/ml: the impact of highly active antiretroviral therapy. AIDS 2005, 19(16):1843-1847.
9. Bonora S., Nicastri E., Calcagno A., Gonzalez de Requena D., D'Ettorre G., Sarmati L., et al. Ultrasensitive assessment of residual HIV viraemia in HAART-treated patients with persistently undetectable plasma HIV-RNA: a cross-sectional evaluation. J Med Virol 2009, 81(3):400-405.
10. Geretti A.M., Smith C., Haberl A., Garcia-Diaz A., Nebbia G., Johnson M., et al. Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy. Antivir Ther 2008, 13(7):927-936.
11. Pham P.A. Antiretroviral adherence and pharmacokinetics: a review of their role in sustained virologic suppression. AIDS Patient Care STDS 2009, 23(10):803-807.
12. Geretti A.M., Doyle T., Smith C., Garcia A., Labbett W., Johnson M., et al. Association between low level viraemia less than 50copies/ml and risk of virologic rebound in HIV-infected patients receiving HAART. 17th Conference on retroviruses and opportunistic infections 2010, [Paper #505].
13. Garcia-Gasco P., Maida I., Blanco F., Barreiro P., Martin-Carbonero L., Vispo E., et al. Episodes of low-level viral rebound in HIV-infected patients on antiretroviral therapy: frequency, predictors and outcome. J Antimicrob Chemother 2008, 61:699-704.
14. Nettles R.E., Keiffer T.L., Kwon P., Monie D., Han Y., Parsons T., et al. Intermittent HIV-1 viraemia (blips) and drug resistance in patients receiving HAART. JAMA 2005, 293:817-829.
15. Havlir D.V., Bassett R., Levitan D., Gilbert P., Tebas P., Collier A.C., et al. Prevalence and predicative value of intermittent viraemia with combination HIV therapy. JAMA 2001, 286:171-179.
16. Deeks S.G., Barbour J.D., Grant R.M., Martin J.N. Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viraemia. AIDS 2002, 16(2):201-207.
17. Dinoso J.B., Kim S.Y., Wiegand A.M., Palmer S.E., Gange S.J., Cranmer L., et al. Treatment intensification does not reduce residual HIV-1 viraemia in patients on highly active antiretroviral therapy. Proc Natl Acad Sci U S A 2009, 106(23):9403-9408.
18. Gandhi R.T., Zheng L., Bosch R.J., Chan E.S., Margolis D.M., Read S., et al. The effect of raltegravir intensification on low-level residual viraemia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. PLoS Med 2010, 7(8). pii:e1000321.